文献速递肿瘤 PET/CT甲状腺核医学

FDG PET评估儿童霍奇金淋巴瘤大肿块化疗四周期后的治疗反应

FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-09-15

基于意大利AIEOP-LH2004试验中309例伴大肿块的儿童霍奇金淋巴瘤患者,其中263例在基线及四周期化疗后行FDG PET评估。PET阴性238例(90.5%)与阳性25例(9.5%)的至进展时间(TTP)有显著差异(平均32.67个月 vs 23.8个月,p<0.0001);CT部分缓解患者中PET仍可区分TTP。多因素分析示PET结果是独立预测因素。

要点

  • 四周期化疗后FDG PET阴性率90.5%,阳性率9.5%,两组TTP差异显著(p<0.0001)。
  • CT部分缓解患者中,PET阳性与阴性TTP分别为24.6个月与34.9个月(p<0.0001)。
  • 多因素分析中仅PET结果是全队列及CT部分缓解亚组的独立预测因素(p<0.01)。

核心结论

  • 四周期化疗后FDG PET反应评估是伴大肿块儿童霍奇金淋巴瘤患者TTP和疾病结局的良好预测因素。
  • 在CT显示部分缓解的患者中,PET能够区分TTP更长的患者。
  • 在伴大肿块的儿童霍奇金淋巴瘤患者及CT部分缓解患者中,FDG PET反应是独立预测因素。

研究设计与样本

  • 分析意大利AIEOP-LH2004试验中703例霍奇金淋巴瘤患者的数据,其中309例伴大肿块,263例在基线及四周期化疗后行FDG PET评估。
  • 患者来自41个意大利中心,2004年3月至2012年9月入组,均接受AIEOP-LH2004方案治疗。
  • 反应判定采用功能与形态学联合标准,以临床监测、仪器检查及组织学数据为参考标准计算TTP和复发率,平均随访43个月。
  • 采用统计学分析比较FDG PET与形态学反应对TTP的预测价值,多因素分析定义独立预测因素。

主要发现

  • 总体反应评估显示PET阴性238例(90.5%),PET阳性25例(9.5%),两组TTP差异显著(平均TTP:阴性32.67个月 vs 阳性23.8个月;p<0.0001,log-rank检验)。
  • 同一队列中CT显示完全缓解85例(32.3%),进展6例(2.3%),部分缓解165例(62.7%);完全缓解与进展患者TTP差异显著(分别为31.1个月和7.9个月;p<0.001,log-rank检验)。
  • PET阳性与PET阴性患者复发率差异显著(p=0000,原文如此)。
  • CT部分缓解患者中,PET阳性与PET阴性TTP差异显著(分别为24.6个月和34.9个月;p<0.0001)。
  • 多因素分析校正多重检验后,仅PET结果在全队列及CT部分缓解亚组中均为独立预测因素(p<0.01)。

关键数值与推荐

  • PET阴性定义为四周期化疗后FDG PET未见异常摄取,本队列238例(90.5%)。
  • PET阳性定义为四周期化疗后FDG PET见异常摄取,本队列25例(9.5%)。
  • CT完全缓解85例(32.3%),部分缓解165例(62.7%),进展6例(2.3%)。

临床怎么用

  • 原文结论认为四周期化疗后FDG PET反应评估是伴大肿块儿童霍奇金淋巴瘤患者TTP和疾病结局的良好预测因素。
  • 原文结论认为在CT显示部分缓解的患者中,PET能够区分TTP更长的患者。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We present the results of an investigation of the role of FDG PET in response evaluation of bulky masses in paediatric patients with Hodgkin's lymphoma (HL) enrolled in the Italian AIEOP-LH2004 trial. METHODS: We analysed data derived from 703 patients (388 male, 315 female; mean age 13 years) with HL and enrolled in 41 different Italian centres from March 2004 to September 2012, all treated with the AIEOP-LH2004 protocol. The cohort comprised 309 patients with a bulky mass, of whom 263 were evaluated with FDG PET at baseline and after four cycles of chemotherapy. Responses were determined according to combined functional and morphological criteria. Patients were followed up for a mean period of 43 months and for each child we calculated time-to-progression (TTP) and relapse rates considering clinical monitoring, and instrumental and histological data as the reference standard. Statistical analyses were performed for FDG PET and morphological responses with respect to TTP. Multivariate analysis was used to define independent predictive factors. RESULTS: Overall, response evaluation revealed 238 PET-negative patients (90.5%) and 25 PET-positive patients (9.5%), with a significant difference in TTP between these groups (mean TTP: 32.67 months for negative scans, 23.8 months for positive scans; p < 0.0001, log-rank test). In the same cohort, computed tomography showed a complete response (CR) in 85 patients (32.3%), progressive disease (PD) in 6 patients (2.3%), and a partial response (PR) in 165 patients (62.7%), with a significant difference in TTP between patients with CR and patients with PD (31.1 months and 7.9 months, respectively; p < 0.001, log-rank test). Similarly, there was a significant difference in relapse rates between PET-positive and PET-negative patients (p = 0000). In patients with PR, there was also a significant difference in TTP between PET-positive and PET-negative patients (24.6 months and 34.9 months, respectively; p < 0.0001). In the multivariate analysis with correction for multiple testing, only the PET result was an independent predictive factor in both the entire cohort of patients and the subgroup showing PR on CT (p < 0.01). CONCLUSION: After four cycles of chemotherapy, FDG PET response assessment in paediatric HL patients with a bulky mass is a good predictor of TTP and disease outcome. Moreover, in patients with a PR on CT, PET was able to differentiate those with a longer TTP. In paediatric HL patients with a bulky mass and in patients with a PR on CT, response on FDG PET was an independent predictive factor.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lopci E, Mascarin M, Piccardo A, et al. FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial. Eur J Nucl Med Mol Imaging. 2018. PMID: 30219963. doi:10.1007/s00259-018-4155-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。